Relationship between chromosomal aberrations and gene expressions in the p53 pathway in chronic lymphocytic leukemia

1Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: What’s ready for prime time use? Haematologica. 2010; 95(1): 12-15.MorenoCMontserratEGenetic lesions in chronic lymphocytic leukemia: What’s ready for prime time use?Haematologica2010951121510.3324/haematol.2009.016873Search in Google Scholar

2Demir V, Kahraman S, Katgı A, Pişkin Ö, Özsan GH, Demirkan F, et al. Kronik lenfositik lösemi hastalarının genel klinik değerlendirilmesi. J DEU Med Fac. 2012; 26(1): 9-19.DemirVKahramanSKatgıAPişkinÖÖzsanGHDemirkanFet alKronik lenfositik lösemi hastalarının genel klinik değerlendirilmesiJ DEU Med Fac2012261919Search in Google Scholar

3Libisch MG, Casas M, Chiribao ML, Moreno P, Cayota A, Osinaga E, et al. GALNT11 as a new molecular marker in chronic lymphocytic leukemia. Gene. 2014; 533(1): 270-279.LibischMGCasasMChiribaoMLMorenoPCayotaAOsinagaEet alGALNT11 as a new molecular marker in chronic lymphocytic leukemiaGene2014533127027910.1016/j.gene.2013.09.052Search in Google Scholar

4Langerbeins P, Groβ-Ophoff-Müller C, Herling CD. Risk-adapted therapy in early-stage chronic lymphocytic leukemia. Oncol Res Treat. 2016; 39(1-2): 18-24.LangerbeinsPGroβ-Ophoff-MüllerCHerlingCDRisk-adapted therapy in early-stage chronic lymphocytic leukemiaOncol Res Treat2016391-2182410.1159/000443013Search in Google Scholar

5Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016; 29(1): 79-89.Amaya-ChanagaCIRassentiLZBiomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markersBest Pract Res Clin Haematol2016291798910.1016/j.beha.2016.08.005Search in Google Scholar

6Jones D. Neoplastic Hematopathology: Experimental and Clinical Approaches. Houston, TX, USA: Humana Press, 2010.JonesDNeoplastic Hematopathology: Experimental and Clinical ApproachesHouston, TX, USAHumana Press201010.1007/978-1-60761-384-8Search in Google Scholar

7Dunphy CH. Molecular Pathology of Hematolymphoid Diseases. Chapel Hill, NC, USA: Springer, 2010.DunphyCHMolecular Pathology of Hematolymphoid DiseasesChapel Hill, NC, USASpringer201010.1007/978-1-4419-5698-9Search in Google Scholar

8Bottoni A, Calin GA. MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microma. 2013; 2(3): 158-164.BottoniACalinGAMicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemiaMicroma20132315816410.2174/2211536602666131126002337Search in Google Scholar

9Shengkan J, Levine AJ. The p53 functional circuit. J Cell Sci. 2001; 114(23): 4139-4140.ShengkanJLevineAJThe p53 functional circuitJ Cell Sci2001114234139414010.1242/jcs.114.23.4139Search in Google Scholar

10Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene. 2005; 24(17): 2899-2908.HarrisSLLevineAJThe p53 pathway: Positive and negative feedback loopsOncogene200524172899290810.1038/sj.onc.1208615Search in Google Scholar

11Levine AJ. p53, The cellular gatekeeper for growth and division. Cell. 1997; 88(3): 323-331.LevineAJp53, The cellular gatekeeper for growth and divisionCell199788332333110.1016/S0092-8674(00)81871-1Search in Google Scholar

12RT2 Profiler PCR Array Data Analysis. 2017 https://dataanalysis.qiagen.com/pcr/arrayanalysis.phpRT2 Profiler PCR Array Data Analysis2017https://dataanalysis.qiagen.com/pcr/arrayanalysis.phpSearch in Google Scholar

13Goldin LR, Slager SL. Familial CLL: Genes and environment. Hematology Am Soc Hematol Educ Program. 2007: 339-345.GoldinLRSlagerSLFamilial CLL: Genes and environmentHematology Am Soc Hematol Educ Program200733934510.1182/asheducation-2007.1.339Search in Google Scholar

14Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910-1916.DöhnerHStilgenbauerSBennerALeupoltEKröberABullingerLet alGenomic aberrations and survival in chronic lymphocytic leukemiaN Engl J Med2000343261910191610.1056/NEJM200012283432602Search in Google Scholar

15The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779-790.The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient dataLancet Oncol201617677979010.1016/S1470-2045(16)30029-8Search in Google Scholar

16Te Raa GD, Kater AP. TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Pract Res Clin Haematol. 2016; 29(1): 90-99.Te RaaGDKaterAPTP53 dysfunction in CLL: Implications for prognosis and treatmentBest Pract Res Clin Haematol2016291909910.1016/j.beha.2016.08.00227742075Search in Google Scholar

17Zenz T, Kröber A, Scherer A, Häbe S, Buhler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood. 2008; 112(8): 3322-3329.ZenzTKröberASchererAHäbeSBuhlerABennerAet alMonoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-upBlood200811283322332910.1182/blood-2008-04-15407018689542Search in Google Scholar

18Zenz T, Mertens D, Döhner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011; 25(3): 131-137.ZenzTMertensDDöhnerHStilgenbauerSImportance of genetics in chronic lymphocytic leukemiaBlood Rev201125313113710.1016/j.blre.2011.02.00221435757Search in Google Scholar

19Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997; 76(7): 935-938.PepperCHoyTBentleyDPBcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistanceBr J Cancer199776793593810.1038/bjc.1997.48722280649328155Search in Google Scholar

20Vucicevic K, Jakovljevic V, Sretenovic J, Tosic N, Kostic T, Glumac I, et al. Expression of the Bcl2 gene in chronic lymphocytic leukaemia patients. Ser J Exp Clin Res. 2015; 16(3): 187-191.VucicevicKJakovljevicVSretenovicJTosicNKosticTGlumacIet alExpression of the Bcl2 gene in chronic lymphocytic leukaemia patientsSer J Exp Clin Res201516318719110.1515/sjecr-2015-0024Search in Google Scholar

21Tsirigotis P, Pappa V, Labropoulos S, Papageorgiou S, Kontsioti F, Dervenoulas J, et al. Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol. 2006; 76(3): 230-236.TsirigotisPPappaVLabropoulosSPapageorgiouSKontsiotiFDervenoulasJet alMutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemiaEur J Haematol200676323023610.1111/j.1600-0609.2005.00604.x16412137Search in Google Scholar

22Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, MiuraY, Takeyama K, et al. Loss of the cyclin-dependent kinase 4-inhibitor (pl6; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995; 86(4): 1548-1556.OgawaSHangaishiAMiyawakiSHirosawaSMiuraYTakeyamaKet alLoss of the cyclin-dependent kinase 4-inhibitor (pl6; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignanciesBlood19958641548155610.1182/blood.V86.4.1548.bloodjournal8641548Search in Google Scholar

23Romagosa C, Simonetti S, López-Vicente L, Mazo A, Leonard ME, Castellvi J, et al. p 16Ink4a Overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011; 30(18): 2087-2097.RomagosaCSimonettiSLópez-VicenteLMazoALeonardMECastellviJet alp 16Ink4a Overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumorsOncogene201130182087209710.1038/onc.2010.61421297668Search in Google Scholar

24Greco R, Sala E, Crucitti L, Morelli M, Stanghellini MTL, Vago L, et al. Pentraxin 3 as a novel diagnostic and prognostic biomarker for acute GvHD and fungal infections in adult allogeneic HSCT recipients. Blood. 2016; 128(22): 4600.GrecoRSalaECrucittiLMorelliMStanghelliniMTLVagoLet alPentraxin 3 as a novel diagnostic and prognostic biomarker for acute GvHD and fungal infections in adult allogeneic HSCT recipientsBlood201612822460010.1182/blood.V128.22.4600.4600Search in Google Scholar

25Ke H-H, Hueng D-Y, Tsai W-C. Low expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomas. Chin J Physiol. 2019; 62(1): 35-43.KeH-HHuengD-YTsaiW-CLow expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomasChin J Physiol2019621354310.4103/CJP.CJP_3_1930942197Search in Google Scholar

26Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study. Medicine. 2018; 97(40): e11780.LiuBZhaoYGuoLIncreased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort studyMedicine20189740e1178010.1097/MD.0000000000011780620052730290589Search in Google Scholar

27Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015; 160(4): 700-714.BonavitaEGentileSRubinoMMainaVPapaitRKunderfrancoPet alPTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancerCell2015160470071410.1016/j.cell.2015.01.00425679762Search in Google Scholar